Buy BeiGene Stock | BGNE Stock Price & Latest News | Public.com
BGNE

BeiGene

$0.00 (0.00%)Today
    View BeiGene (BGNE) stock trends here

    About BGNE

    BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317),...Read more

    Buy any stock with any amount of money.

    Download the App
    Download the app

    What Wall Street Thinks

    Events

    List of events that could affect this stock.

    Earnings

    The value each share was expected to gain vs. the value that each share actually gained

    0
    -1.73
    -3.47
    -5.2
    Q2 2020
    Q3 2020
    Q4 2020
    Q1 2021

    Expected EPS
    Q1 2021

    -$3.11

    Actual EPS
    Q1 2021

    Stats

    Market Cap$27,57B
    Volume254,14k
    Price-to-Earnings Ratio
    Dividend Rate
    Dividend Yield
    1 Year High$388.97
    1 Year Low$118.55
    Open$292.02
    High$305.60
    Low$283.50

    Buy any stock with any amount of money.

    Download the App
    Download the app